Sekretessinställningar
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Aktiemarknader
    • BörsRealtidskurser, index och marknadsutveckling
    • MorgonrapportDaglig marknadssammanfattning och nattens viktigaste händelser
    • BörskalenderKommande resultat, noteringar och företagshändelser
    • UtdelningskalenderKommande och tidigare utdelningar
  • Bolag
    • BolagBläddra och filtrera hela listan över noterade bolag
    • UpptäckInspiration till din nästa investering
    • BörsnoteringarNya noteringar och kommande börsintroduktioner
    • ÅrsstämmorDatum för årsstämmor och aktieägarinformation
  • Aktieforskning
    • AktieanalysExpertaktieanalys och rekommendationer
    • ArtiklarNyheter, insikter och marknadskommentarer
    • PortföljInderes modellportfölj
    • inderesTVVideohub för aktieanalys, forskning och expertkommentarer
    • TranskriptionerFullständiga utskrifter av resultatsamtal och investerarmöten
    • AktiejämförelseJämför nyckeltal och utveckling för flera aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • BlankningSe vilka börsnoterade bolag som har offentliggjorda korta positioner
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Q&A
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer

Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.

Transkriptioner

Läs transkriptioner från webbsändningar och audiocasts

Transkriptioner

Läs transkriptioner från webbsändningar och audiocasts

Alla regioner
Sverige
Finland
Danmark
Norge
Senaste
Trendande
Följda

ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report

Av HC Andersen Capital2026-11-12 09:00
ExpreS2ion Biotech

Ansvarsfriskrivning: Detta är en maskin­genererad transkription och kan innehålla felaktigheter.

Michael
00:00 - 00:49

Welcome to today's presentation, where we have the pleasure to present ExpreS2ion Biotech Holding AB; to help us through today's presentation, we are joined by CEO Bent U. Frandsen and CFO Keith Alexander. The topic for today is the Q3 results. But of course, also news from the pipeline during the quarter, which we will go through in this event; as always, there's a box down below to feel free to ask questions. The Q&A will be held at the end. Feel free to ask questions in Danish. I will try and translate to the best of my ability. We have a fixed schedule to do half an hour and we will keep that fixed deadline. But on the last slide, there will be an email address where you can send in the questions if we should not catch them. But with that, I will hand the stage over to you, Bent.

Bent U. Frandsen
00:50 - 13:23

Thank you very much, Michael. And welcome everybody to ExpreS2ion. Q3 2026 result webcast. I am the CEO of the company, and I am joined today by our CFO, Keith Alexander. I will begin with our operational and clinical progress, including our platform partnerships. And the latest update on ES2B-C001. Our HER2-targeting breast cancer immunotherapy. And then Keith will take us through the third quarter and nine months financial results before we open for questions. Before we begin, please note the disclaimer on this slide. Today's presentation includes forward-looking statements, particularly on clinical development, partnering, and funding. These reflect our current expectations and are subject to risks and uncertainties, so actual outcomes and timing may differ. Let me start with three reasons why this is an important period for ExpreS2ion. First, we have observed anti-HER2 antibody responses in 12 out of 13 evaluable patients in our Phase I clinical trial. These are preliminary findings, but they support the biological rationale for ES2B-C001, second, in the market. There is still a substantial need for more durable disease control. Even with the strong results reported for newer first-line HER2 combinations, around 3 in 10 patients have progressed or passed away within two years. And third, our Phase I primary readout is expected in the first quarter of 2027. That dataset, together with the translational work, will be central to our partnering discussions and the next development decision. Our pipeline has a clear focus on one proprietary oncology lead asset supported by a broader group of partnered infectious disease programs; we sponsor ES2B-C001 ourselves. Our malaria, Nipah virus, and influenza activities are advanced through licenses, academic collaborations, and grant funding with different levels of funding coverage. This structure allows us to focus our own investment on oncology, while continuing to demonstrate the capabilities of the ExpreS2ion platform across other applications. The pipeline chart also shows the historical COVID-19 program, which reached phase three before Bavarian Nordic discontinued it for commercial reasons. I will now move more in-depth into our platform. So ExpreS2 is the protein expression platform behind our programs since 2010. It has been used to express more than 500 proteins and virus-like particles, with a success rate above 90%. Its clinical track record includes the COVID-19 program, whose Phase III study enrolled more than 4,200 participants and met its primary endpoint, demonstrating non-inferiority against a commercial mRNA vaccine. Published work demonstrated production of more than 400mg of RH5.1 antigen from a single 25-liter cGMP batch, which demonstrates solid experience in this field. For ExpreS2, this platform supports several sources of income and funding: technology licenses, contract research, and grant-funded programs. The Serum Institute of India Malaria Agreement from November 2025 is an important example. Glycan engineering patent applications published this year also extended our intellectual property estate. In malaria, our platform produces four antigens for the University of Oxford. Development programmes at RH5.1 and R78C are particularly relevant commercially because they are licensed to the Serum Institute of India. During the quarter, a Phase IIb trial of RH5.1 concluded, as did the Phase Ib/II trial combining RH5.1 and R78C. Two new trials involving combinations with the W.H.O. recommended R21 vaccine are being prepared, and further Phase IIb completion is expected in the fourth quarter. Several important data sets are expected in the first quarter of 2027, including longer-term RH5.1 follow-up and combination data. The University of Oxford determines the timing, which may change. The need remains very large. Still, more than 600,000 died from malaria in 2024, mostly among young children in Africa. For us, the Serum Institute of India license offers potential milestones and royalties as development and commercialization progress, as we announced in November 2025. The other Oxford programs provide additional clinical experience with our platform. Nipah is another important application for our platform. Recurring outbreaks, high fatality rates, and the absence of an approved vaccine underscore the need for a preventive option. Underline the need for a preventive option during Q3 work. Continue to finalize the cGMP-ready antigen process, and cGMP manufacturing is underway at Northway Biotech. The next steps are the toxicology study, the clinical trial application, and a Phase I/IIa trial run by the consortium. The program is grant-funded to Phase I and combines ExpreS2-produced antigen with VLP technology, the same overall approach used for ES2B-C001 cancer immunotherapy and the Covid-19 vaccine. Because that antigen is made with ExpreS2, we expect our technology to form part of any future licensing agreement, although no such outcome is assured. We expect our technology to form part of any future licensing agreement, although no such outcome is assured. MucoVax, meanwhile, is approximately 67% grant-funded. It's work on cell lines. Large-scale antigen production will be key. Purification also contributes to the platform's capabilities. Let me turn to ES2B-C001, our lead asset, and explain where we believe active immunotherapy could contribute to the treatment of HER2-expressing cancers. Treatment for HER2-positive metastatic breast cancer has advanced considerably. Antibody-drug conjugates, or ADCs, have raised the standard that new approaches must meet, as seen in the DESTINY-Breast09 trial of trastuzumab deruxtecan. Enhertu, also known as fam-trastuzumab deruxtecan, delivered a median progression-free survival of around 41 months. Nevertheless, around 30% of patients had progressed or passed away by two years. That remaining gap is relevant to our development strategy. ES2B-C001 is designed to add an active, broad anti-HER2 immune response to standard treatment with the aim of extending disease control. We see it as a potential complement to existing therapies, including ADCs. The historical comparisons on this slide illustrate progress in the field, though not head-to-head comparisons across trials, and the intended benefit of adding ES2B-C001, of course, still needs to be tested clinically. Our current study is establishing safety and immune responses. ES2B-C001 combines the full extracellular part of HER2 produced using ExpreS2 with high-density display on a virus-like particle. That extracellular region contains four domains. Individual HER2-directed. Monoclonal antibodies bind to specific sites. By presenting all four domains, ES2B-C001 is designed to stimulate a broader family of antibodies against HER2. One is designed to stimulate a broader family of antibodies against HER2. The VLP provides a repetitive display intended to help the immune system generate a strong and lasting response. There is established experience with durable antibody responses to VLP-based infectious disease vaccines, for example with HPV vaccines. That experience supports the rationale for our design. Our own Phase I follow-up and planned maintenance boosters are intended to address these questions alongside translational analyses of antibody quality and function. Turning to the clinical data. This is an open-label, Phase I dose-escalation study in patients with advanced HER2-positive or HER2-low breast cancer after standard treatment. It evaluates five intramuscular doses across three cohorts: 50, 150, and 450 micrograms. The main objectives are safety, tolerability, and immunogenicity. 19 patients have been dosed in the preliminary evaluable dataset. 12 of 13 patients showed at least a two-fold increase in anti-HER2 antibody titers. Looking at the graph, titers rise over the dosing series and then decline gradually after the fifth dose. Individual patterns varied, and the graph uses a data cutoff of October 5th. Follow-up and planned boosters will help us understand how these responses can be maintained, and we continue to monitor safety. No dose-limiting toxicities and no treatment-related serious adverse events have been reported in the data presented here. The Independent Safety Monitoring Board has cleared continuation. These are encouraging early observations, but the study is small and findings remain preliminary. This translational work will examine immune quality, durability, and mode of action, together with the primary readout expected in Q1 2027. This should provide a more complete basis for deciding how to take this to ES2B-C001 forward. Our immediate priorities are to complete Phase I dosing in the fourth quarter. Obtain translational results. Obtain translational results around the end of the year, and deliver the primary Phase I readout in the first quarter of 2027. For Phase II, the proposed focus is first-line HER2-positive metastatic breast cancer. Informed by our Scientific Advisory Board discussions. This would give us a more homogeneous population with better-preserved immune function than in a heavily pretreated setting. We are planning a focused study of 80 to 120 patients. The intention is to use one standard of care backbone across all arms, so we can assess the contribution of ES2B-C001 within a standard of care setting. The proposed main readout is progression-free survival at 24 months. Tumor-informed circulating tumor DNA, or ctDNA, is planned as a key secondary endpoint, providing another way to follow disease activity alongside clinical assessments. The design remains subject to protocol finalization, statistical validation, and regulatory interaction. The dose arms are not yet fixed. A 24-month endpoint also requires sufficient patient follow-up. The eventual readout date will depend on recruitment and the final study design. Our preferred partnering model is for the partner to fund Phase II and collaborate on development, with an option to license after interim data. This is a model we are pursuing with a partner. We are targeting a Phase II start in the second half of 2027, subject to funding and other development requirements. That concludes my operational and clinical update. I will now hand over to Keith to take us through the Q3 and nine months 2026 financial results. Keith, over to you.

Keith Alexander
13:27 - 21:50

Thank you. I will now take you through the financial results for Q3 and the first nine months of 2026. As Bent described, we made significant clinical progress in the quarter. I will show you what that looked like in the numbers, starting with the headline figures. Operating income was 2.3 mSEK, essentially flat year-on-year. Operating loss increased 31% year on year to 12.8 mSEK, and the net loss for the period was 9.9 mSEK, up 18% from Q3 2025. On cash, we closed the quarter with 24 million, before 19.3 million in proceeds from the TO13 warrant exercise and the directed issue to the guarantor. Most of which was received after the period. The R&D spend figure of 3.7 million SEK was up 56% year-on-year. I will go into more detail on these figures in the coming slides. Let's look at income in a bit more detail. The left chart shows total operating income per quarter since 1Q24; Q3 2026 was much lower than recent quarters at 2.3 million, but essentially flat versus Q3 2025. That decrease is from the grants line. Net sales were 1.4 million, up 0.4 million from Q3 2025, reflecting more customer project activity. The percentage looks large because Q3 last year was the weakest quarter on this chart. The better measure is year-to-date. Net sales are up 37% to 4.4 million. Other operating income, which is mainly grant income, was 0.9 million SEK, down 52% year on year. We recognize grant income as the funded work is done, so it follows the timing of project activity rather than coming in evenly. The bigger fall is against Q2; as the call-out shows, Q2 included grant income for the disease manufacturing work we subcontracted, with matching costs in R&D. That campaign is now largely complete. So, as I said last quarter, both the grant income and the matching R&D costs will be much lower from here. Turning to costs, total operating expenses were 15.1 million SEK, up 25% year-on-year. The left chart shows a quarterly progression, including a significant decrease in sequential operating expenses. R&D costs were 3.7 million SEK, up 56% year on year. That was mainly due to ES2B-C001 clinical trial costs alongside higher CMC costs. Against Q2, they were much lower because Q2 carried most of the infectious disease manufacturing costs. Manufacturing costs. Personnel costs were 7.4 million, up 25% year on year. That reflects higher personnel-related expenses and a soft comparison, because Q3 2025 benefited from parental and sick leave reimbursements. Other external costs were 3.0 million, up 18%, mainly from higher legal and professional fees, partly offset by lower costs elsewhere. This quarter, we would like to show you an estimate of our year-to-date operational expenses, split by the main activities and how they compare with the same period for 2025. These buckets are ES2B-C001. Infectious diseases, which are other pipeline activities in malaria, influenza and Nipah virus. Serum platform activities and other costs, which are primarily administrative and due to being a publicly listed company. It is a rough management estimate based on direct costs and the time that our team registers against each program and allocation rules for non-program-specific activities, such as rental facilities. For that reason, it is important to stress that the allocated structure pictured here is our estimate. Operating costs for the first nine months rose from 42.8 million in 2025 to 57.4 million in 2026. Most of that increase was offset by higher grant income, so our net operating costs rose by only around 2.6 million SEK. The big change is in infectious diseases, which has taken a much larger share of our costs this year. That is mainly the Nipah virus program moving towards cGMP manufacturing in the VICI-Disease Consortium. Grants covered about 70% of infectious disease-related costs, up from around 60% in 2025. With the manufacturing campaign now largely complete, both the cost and the matching grant income will be lower from here. Finally, ExpreS2ion's share is slightly lower only because infectious diseases grew in absolute terms, with spending on it rising, driven by clinical costs. The net loss for the period was 9.9 million SEK, compared to 8.4 million SEK in Q3 2025, an 18% increase. The bottom-left chart breaks down the drivers. The operating result deteriorated by 3 million. Net financial items were a small benefit of 319,000 SEK, and the R&D tax credit accrual increased by 1.2 million SEK, reflecting the higher qualifying R&D spend in the period. Those three factors together account for the 1.5 million SEK increase in the net loss. So it is primarily driven by the operating result. Looking at the year-to-date loss on the right side, the loss decreased 2% in 2026 compared with the year-to-date 2025 result. The bottom right chart breaks this down. The drivers' operating result was slightly worse, while net financial items and the R&D tax credit were better year-to-date than in the first nine months of 2025. This drove a total improvement of approximately 700,000 SEK. The waterfall chart shown here shows cash development over the last year from September 2025 through to September 2026. We started at 36.9 million SEK, with operating cash outflows through the year. Reflects continued investment in ES2B-C001 and grant-funded program activities. We closed Q3 2026 at 24 million SEK, and the single largest driver in Q3 was the operating cash flow of -11.1 million SEK, compared with -12.5 million SEK in Q2 and -25.5 million SEK in Q1. The final quarter of 2025, and the last several years more broadly, have benefited from the annual payment of the R&D tax credit, which is usually in November. Operating cash flow is still primarily driven by ES2B-C001 clinical development. While ExpreS2ion's role in the VICI-Disease consortium's CMC is mostly behind us. As I mentioned, looking forward to infectious disease programs. CMC costs and income are expected to be much lower. Pulling it together on the cash outlook, Q3 2026 closing cash was 24 million SEK after the quarter. The TO3 warrant exercise and the directed issue to the guarantor brought in 19.3 million SEK before issue costs. That came with a dilution of about 40%. The net proceeds are intended primarily to take ES2B-C001 through the primary readout of its Phase I clinical trial. It's in September, and we also signed a put option agreement with Alumni Capital for up to 50 million SEK over 24 months, starting in 2027. You can choose whether and when to use it, but we can only give notice to draw on it when the share price is at or above 4.00 SEK. The share price is well below that today, so it is not in our current forecast. It's an option that could become useful under the right conditions, including a higher share price. Our priorities are to complete the Phase I priming phase for ES2B-C001 in December. Deliver the translational studies before year-end. Support the target of Q1 2027 primary readout and advance related business development activities. Timing remains subject to clinical, regulatory, operational, and funding factors as set out in the presentation that covers the financial section. With that, I'll hand it back to Bent for some comments on expected milestones over the next 12 months, and stay online for the Q&A.

Bent U. Frandsen
21:51 - 23:25

Thank you Keith. And before we take questions, let me close with the key milestones ahead. So our main priority is the ES2B-C001 phase one primary readout in the first quarter of 2027. Alongside safety and immune responses. We expect preliminary observations of anti-tumor activity assessed using RECIST criteria. And together with our translational work, the readout will inform the phase two design and support partnering discussions. We're working towards a focused study in first-line HER2-positive metastatic breast cancer, with the start targeted for the second half of 2027, subject to securing a partner and funding. Across our partner programs, Nipah virus is progressing towards toxicology and the work needed to support a clinical trial application, with potential Phase I initiation in the second quarter of 2027. In malaria, selected clinical readouts, including Phase IIb data, are expected in the first quarter. Selected clinical readouts, including Phase IIb data, are expected in the first quarter. Any additional licensing opportunities remain to be determined. These timelines remain subject to clinical progress, regulatory actions, manufacturing, funding, and partner decisions. Our focus is to turn the emerging clinical and translational evidence into a clear next development step for ES2B-C001, while our partner programs continue to advance. Thank you for your attention and continued interest in ExpreS2ion. Keith and I are happy to take questions.

Michael
23:26 - 23:42

Let's jump into some questions for both. Are there any milestones in Q1 from the SII, upon the presentation of the data? Here we are talking about the malaria. I don't know whether you want to comment on that, but are there any potential milestones from that?

Bent U. Frandsen
23:43 - 23:45

From the malaria program. Sorry.

Michael
23:45 - 23:45

From the malaria.

Bent U. Frandsen
23:45 - 24:24

As I mentioned, there are quite a number of clinical trials going on through the University of Oxford, and several of them are progressing, and we will have more data from the phase two studies that I just highlighted earlier. And of course, with respect to the Serum Institute of India, the tech transfer for RH5.1 and R78C has taken place, meaning that they are starting to scale up manufacturing for later stage clinical trials on those as well. So progressing well.

Michael
24:24 - 24:32

Yes, regarding milestones. I do not know whether you want to comment on whether some money will flow to you. On the data front, we are focused on finishing these.

Bent U. Frandsen
24:33 - 24:48

There are certain milestones. I will refer to the press release that we did one year ago in November 2025, where we detailed the financial implications.

Michael
24:49 - 25:00

And moving on to this, we talked about the sale. But the focus is also on the malaria front and so on. Are there any updates on the negotiations you have with them?

Bent U. Frandsen
25:02 - 25:04

I did not quite catch the question. I am sorry.

Michael
25:05 - 25:20

Yes, is there any progress to report on? The agreement you also did with the cell line, I think we have covered. But regarding those, I think you signed a letter of intent with them. Any updates? Any progress?

Bent U. Frandsen
25:21 - 26:04

That is correct; we have a letter of intent stipulating a potential strategic collaboration with WuXi Biologics. It depends on a potential partner applying our ExpreS2 platform in a setting with biologics. And so far, we have actually not been fortunate that WuXi Biologics has retained any client for our platform. It is still ongoing, and we are very pleased that they actually promote our system at various scientific and technological conferences. But that ends today.

Michael
26:06 - 26:26

The first maintenance dose was given in December. Do you have any early indication of whether boosting lifts titers above the priming peak? So, a little bit into the data. I do not know whether you want to go into such details before we have those results. But whether boosting lifts titers above the priming peak.

Bent U. Frandsen
26:26 - 26:49

It is a bit too early to say. We have just initiated the booster phase or the maintenance phase. It is too early to say based on one or two single shots with the patients so far. But of course, we will observe this very carefully during 2027 and bring it into our communication as soon as we can.

Michael
26:50 - 27:14

And then a little bit about the partnership discussion. If we are standing here, is it effectively awaiting for the Q1 2027 readout? Are there any realistic paths to an agreement before that? So, do you feel regarding the partner discussions whether something could actually come before it is really awaiting those Q1 2027 readouts.

Bent U. Frandsen
27:14 - 27:51

The partner discussions are very dependent on the data that we generate. And as we've explained, we have a very compelling preclinical data package. And now it is our task to document what we found in clinical settings, also in the clinical trial. And the Phase I clinical trial is primarily a safety and tolerability trial. We have some indications of anti-tumor activity, which we will announce also in Q1 2027, and that will certainly facilitate the partnering discussions we are in.

Michael
27:52 - 28:00

Perfect. Does the current cash runway? Will it take you through the Q1 2027 readout, including maintenance dosing?

Keith Alexander
28:01 - 28:36

Sure, I can take that one. Well, as we stated, we closed the quarter with about 24 million Swedish crowns in cash, and after that, we received 19.3 million gross from the TO3 and the directed issue. Those proceeds on that basis are intended primarily to take ES2B-C001 through the phase I clinical trial primary readout in the first quarter. We do not provide a specific runway date. What I can say is that the board is continually evaluating our financing needs and our cost base, including financing options, partnership opportunities, and other non-dilutive funding sources.

Michael
28:37 - 29:24

And then the final question: winning back investor confidence. As stated here, you are in a solid cash position. You actually have a solid pipeline. You are in the cancer field where you are showing promising results that must create some new attention around the world. With all those results and perhaps shifting some focus away from the obesity sector where capital is currently concentrated, placing weight on these solid results, you also have this stake in that backlog. So clearly that is where we are, and everybody can state that. But, is winning back investor confidence a game of commercializing, getting the partner, and the data out? Yes, maybe it was a leading question, but I would appreciate your comments on that.

Bent U. Frandsen
29:24 - 30:26

But I think commercialization is the key word. We have a very strong scientific platform and foothold, which has been documented over and over again in malaria, COVID-19, and now also in oncology. But the real value trigger. I acknowledge that must be a partnering event that can trigger a milestone or upfront payments and royalties down the road. And we've seen evidence of this in Swedish publicly listed companies here in 2026. I think there have been some interesting cases of scientifically well-based biotech companies that have been living a strange life, because you also need a commercial outcome of all your scientific wonders. And we are looking to do the same. That is our aim for 2027.

Michael
30:27 - 30:37

Perfect. That was the last question. I will let you off the hook. You both, thank you for taking us through your results and answering questions. In the end of everything. May everybody have a nice day.

Keith Alexander
30:37 - 30:38

Thank you.

Till webcasten
Pierce Group, Audiocast, Q3'26
Språk: Engelska2026-11-13 08:00
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Språk: Engelska2026-11-12 10:00
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Språk: Engelska2026-11-12 09:00
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Språk: Engelska2026-11-12 08:00
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Språk: Engelska2026-11-12 08:00
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Språk: Svenska2026-11-12 08:00
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Språk: Engelska2026-11-12 08:00
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Språk: Engelska2026-11-12 07:15
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Språk: Engelska2026-11-11 13:00
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Språk: Engelska2026-11-11 13:00
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Språk: Engelska2026-11-11 12:30
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Språk: Engelska2026-11-11 09:00
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Språk: Engelska2026-11-11 09:00
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Språk: Engelska2026-11-10 17:00
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Språk: Engelska2026-11-10 08:00
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Språk: Engelska2026-11-10 08:00
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Språk: Svenska2026-11-06 09:00
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Språk: Engelska2026-11-06 09:00
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Språk: Engelska2026-11-06 09:00
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Språk: Engelska2026-11-06 09:00
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…